INT301 Continues to Meet Safety Goals in Phase 1 OMEGA Study in Adults with Peanut Allergy While Reaching Phase 2 Target Maintenance Dose
INT301 Met Safety Goals Across Eleven Dose Levels Patient Treatment Now Ongoing in Cohort 3 Intrommune Expands Study Scope to...